Cytori Therapeutics Inc Stock Nasdaq
Stocks
US23283K1051
Biotechnology & Medical Research
| Market Cap | 13.21M 11.85M 10.95M 9.92M 18.53M 1.26B 18.76M 131M 52.17M 658M 49.56M 48.51M 2.09B | P/E 2026 * |
-0.37x | P/E 2027 * | -0.7x |
|---|---|---|---|---|---|
| Enterprise Value | 13.21M 11.85M 10.95M 9.92M 18.53M 1.26B 18.76M 131M 52.17M 658M 49.56M 48.51M 2.09B | EV / Sales 2026 * |
3.55x | EV / Sales 2027 * | 0.69x |
| Free-Float |
97.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytori Therapeutics Inc
| 1 day | -1.85% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 2014-04-01 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 2020-02-05 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 2025-10-20 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 2002-09-30 |
Richard Hawkins
CHM | Chairman | 77 | 2018-01-24 |
| Director/Board Member | 66 | 2019-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.85% | -29.07% | - | - | 13.21M | |
| +0.65% | -3.36% | +36.98% | +60.50% | 64.14B | |
| +1.76% | +1.27% | +11.82% | +81.21% | 55.53B | |
| -0.94% | +0.99% | +10.45% | +100.19% | 53.03B | |
| +2.76% | +0.87% | +27.92% | +55.07% | 45.99B | |
| +2.00% | -3.39% | +17.83% | +119.04% | 42.45B | |
| +1.34% | -2.86% | +224.43% | +914.08% | 40.45B | |
| +0.64% | -3.95% | +11.15% | +45.57% | 32.25B | |
| +29.06% | +47.63% | +107.12% | +92.73% | 34.47B | |
| -2.63% | -0.40% | +23.24% | -10.73% | 24.23B | |
| Average | +3.27% | +4.08% | +52.33% | +161.96% | 43.62B | |
| Weighted average by Cap. | +3.34% | +3.49% | +49.21% | +159.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.72M 3.34M 3.09M 2.79M 5.22M 354M 5.28M 36.89M 14.69M 185M 13.96M 13.66M 588M | 19.14M 17.17M 15.88M 14.38M 26.86M 1.82B 27.19M 190M 75.61M 954M 71.83M 70.31M 3.03B |
| Net income | -32.63M -29.28M -27.07M -24.52M -45.8M -3.11B -46.36M -324M -129M -1.63B -122M -120M -5.16B | -19.05M -17.1M -15.81M -14.31M -26.74M -1.81B -27.07M -189M -75.27M -950M -71.5M -70M -3.01B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
